China
approves use of GSK
vaccine Cervarix for
cervical cancer
HONG KONG (Reuters) - Drugmaker GlaxoSmithKline Plc said on Monday the
China Food and Drug Administration (CFDA) has approved its human papillomavirus (HPV) vaccine, Cervarix, for use in the country to help women fight
cervical cancer.
